<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03736564</url>
  </required_header>
  <id_info>
    <org_study_id>17-008120</org_study_id>
    <nct_id>NCT03736564</nct_id>
  </id_info>
  <brief_title>Ga-DOTATATE PET for Phosphaturic Mesenchymal Tumors in Patients With Tumor Induced Osteomalacia</brief_title>
  <official_title>68Ga-DOTATATE PET for Localization of Phosphaturic Mesenchymal Tumors in Patients With Tumor Induced Osteomalacia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The researchers are trying to evaluate a newer imaging technique (Ga-DOTATATE PET/CT) to see
      if it is more sensitive to localize the source of the hormone, which has caused the low
      phosphate levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be contacted (phone script attached) to inform them of the study and the
      imaging modality. The first 10 patients that agree to participate in the study will be asked
      to present to the Mayo Clinic where they can provide a written consent and perform the
      imaging study.

      Enrolled subjects will be evaluated in the clinical practice prior to having 68Ga-DOTATATE
      PET/CT imaging performed. The treating endocrinologist will be informed of the imaging
      results and will review the results with the subject using a follow-up visit or phone call;
      when a tumor is localized, the endocrinologist will discuss appropriate management options.

      Subjects will be follow for one year post 68Ga-DOTATATE PET/CT.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 31, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>68Ga-DOTATATE PET Positive Maximum Intensity Projection</measure>
    <time_frame>One year</time_frame>
    <description>68Ga-DOTATATE PET maximum intensity projection images will be analyzed to evaluate for the localization of phosphaturic mesenchymal tumors (PMTs).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Osteomalacia</condition>
  <arm_group>
    <arm_group_label>68Ga-DOTATATE PET/CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will undergo imaging by 68Ga-DOTATATE PET/CT</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>68Ga-DOTATATE PET/CT</intervention_name>
    <description>Gallium-68 Dotatate, a radioactive imaging agent, is injected into a vein. Subjects will rest for approximately 50 minutes, after which approximately a 30 minute image of subjects body will be completed via PET/CT scan.</description>
    <arm_group_label>68Ga-DOTATATE PET/CT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (18 years of age or older) seen at Mayo Clinic, Rochester for FGF23 mediated
             osteomalacia between 1/1/2000 and 1/30/2018 who provide informed consent to
             participate in the study.

        Exclusion Criteria:

          -  Pregnant

          -  Prisoners

          -  Subjects diagnosed with heritable hypophosphatemic rickets/osteomalacia

          -  Subjects who do not consent for the study or withdraw consent during the duration of
             the study.

          -  Subjects in whom tumor localization and successful resection has already occurred.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Drake, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen M Broski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Tebben, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jad Sfeir, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jad Sfeir, MD</last_name>
    <phone>507-284-2617</phone>
    <email>Sfeir.Jad@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vishakantha (Vishu) Murthy, PhD</last_name>
    <phone>507-255-8112</phone>
    <email>Murthy.Vishakantha@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jad Sfeir, MD</last_name>
      <phone>507-284-2617</phone>
      <email>Sfeir.Jad@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Vishakantha (Vishu) Murthy, PhD</last_name>
      <phone>507-255-8112</phone>
      <email>Murthy.Vishakantha@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Matthew Drake, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephen M Broski, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Tebben, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jad Sfeir, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 30, 2018</study_first_submitted>
  <study_first_submitted_qc>November 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2018</study_first_posted>
  <last_update_submitted>March 31, 2020</last_update_submitted>
  <last_update_submitted_qc>March 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Matthew Drake, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>FGF 23</keyword>
  <keyword>oncogenic</keyword>
  <keyword>tumor induced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteomalacia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

